IOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IOL Chemicals reported standalone revenue of Rs 2,319.06 crore for FY2026, up 11.5% from Rs 2,079.21 crore in FY2025. Profit after tax grew 36.4% to Rs 137.72 crore from Rs 101.00 crore, with EPS improving from Rs 3.44 to Rs 4.69. EBITDA margin expanded from 10.4% to 11.5%, indicating improved operational efficiency. The auditors issued an unmodified opinion with no going concern issues. An exceptional item of Rs 11.21 crore was recognized in Q3 due to past service costs from new labour code amendments. The company also announced new capacity additions: 6,000 MTPA for Triacetin (Rs 16.88 crore) and capacity enhancement for Pantoprazole from 240 to 276 MTPA (Rs 5.87 crore), both funded through internal accruals.
Strong bottom-line growth with PAT up 36% and margin expansion signals operational efficiency gains. The clean audit opinion and capacity expansion plans indicate a healthy outlook, though the one-time labour code charge may affect comparability.